- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Piramal Pharma Moves to Make Yapan Bio Wholly Owned Subsidiary

Mumbai: Piramal Pharma Limited has approved the exercise of its call option to acquire the remaining 26% equity stake in Yapan Bio Private Limited, a subsidiary of the company, taking its shareholding from the existing 74% to 100%.
In a disclosure, Piramal Pharma informed that the Administrative Committee of its Board of Directors, acting under the authority delegated by the Board, had approved the exercise of the call option to acquire the balance stake in Yapan Bio from its existing shareholders.
Following the exercise of the call option, the company is currently engaged in discussions with Yapan Bio's existing shareholders regarding various matters necessary for completing the proposed transaction.
However, the final terms of the acquisition, including the acquisition consideration and the effective date of the transfer of shares, are yet to be finalised. The company stated that it would make appropriate disclosures, including the details required under Regulation 30 of the SEBI Listing Regulations, upon execution of the definitive documentation and completion of the proposed transaction.
Yapan Bio Private Limited is a Contract Development and Manufacturing Organization (CDMO) specialising in process development, characterisation and Phase I/II Good Manufacturing Practice (GMP) manufacturing services for vaccines and biologics.
Upon completion of the proposed acquisition, Piramal Pharma's shareholding in Yapan Bio is expected to increase from the current 74% to 100%, making Yapan Bio a wholly owned subsidiary of Piramal Pharma Limited.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

